Used in the development of targeted protein degradation therapies, particularly in PROTAC (proteolysis targeting chimera) technology. The compound functions as a linker that connects a thalidomide derivative—known for binding to the E3 ubiquitin ligase complex—to a target protein ligand. This enables selective ubiquitination and subsequent degradation of disease-related proteins via the cell’s proteasome system. Its PEG-based spacer provides enhanced solubility and flexibility, improving cellular permeability and degradation efficiency. Commonly applied in research for oncology, neurodegenerative diseases, and inflammatory conditions where selective removal of specific proteins is desired.